Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2020 1
2021 3
2022 1
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D; SAMCO-PRODIGE 54 Investigators. Taïeb J, et al. JAMA Oncol. 2023 Oct 1;9(10):1356-1363. doi: 10.1001/jamaoncol.2023.2761. JAMA Oncol. 2023. PMID: 37535388 Free PMC article.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
Turpin A, Delliaux C, Parent P, Chevalier H, Escudero-Iriarte C, Bonardi F, Vanpouille N, Flourens A, Querol J, Carnot A, Leroy X, Herranz N, Lanel T, Villers A, Olivier J, Touzet H, de Launoit Y, Tian TV, Duterque-Coquillaud M. Turpin A, et al. Among authors: carnot a. Br J Cancer. 2023 Dec;129(12):1903-1914. doi: 10.1038/s41416-023-02449-x. Epub 2023 Oct 24. Br J Cancer. 2023. PMID: 37875732 Free PMC article.
Iron deficiency in patients with cancer: a prospective cross-sectional study.
Luporsi E, Turpin A, Massard V, Morin S, Chauffert B, Carnot A, Cacoub P; Behalf of the CARENFER Study Group. Luporsi E, et al. Among authors: carnot a. BMJ Support Palliat Care. 2021 Jul 30:bmjspcare-2021-002913. doi: 10.1136/bmjspcare-2021-002913. Online ahead of print. BMJ Support Palliat Care. 2021. PMID: 34330792
Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).
Strobbe G, Gaboriau L, Abelé M, Villain A, Aelbrecht-Meurisse C, Carnot A, Le Deley MC, Léguillette C, Feutry F, Sakji I, Marliot G. Strobbe G, et al. Among authors: carnot a. Eur J Clin Pharmacol. 2023 Sep;79(9):1229-1238. doi: 10.1007/s00228-023-03536-x. Epub 2023 Jul 13. Eur J Clin Pharmacol. 2023. PMID: 37438439
EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report.
Dansin E, Carnot A, Servent V, Daussay D, Robin YM, Surmei-Pintilie E, Lauridant G, Descarpentries C, Révillion F, Delattre C. Dansin E, et al. Among authors: carnot a. Case Rep Oncol. 2015 Mar 14;8(1):164-8. doi: 10.1159/000381014. eCollection 2015 Jan-Apr. Case Rep Oncol. 2015. PMID: 25873885 Free PMC article.
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A. Martinez Chanza N, et al. Among authors: carnot a. BMC Cancer. 2021 Dec 2;21(1):1292. doi: 10.1186/s12885-021-08990-3. BMC Cancer. 2021. PMID: 34856936 Free PMC article. Clinical Trial.
Diagnostic Value of the Texture Analysis Parameters of Retroperitoneal Residual Masses on Computed Tomographic Scan after Chemotherapy in Non-Seminomatous Germ Cell Tumors.
Fournier C, Leguillette C, Leblanc E, Le Deley MC, Carnot A, Pasquier D, Escande A, Taieb S, Ceugnart L, Lebellec L. Fournier C, et al. Among authors: carnot a. Cancers (Basel). 2023 May 31;15(11):2997. doi: 10.3390/cancers15112997. Cancers (Basel). 2023. PMID: 37296963 Free PMC article.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0207. Online ahead of print. JAMA Oncol. 2024. PMID: 38573643
14 results